Australia: Patentability of genetic material - where does it stand today?

Last Updated: 12 September 2013
Article by Catherine Logan and Calvin Lau

This article was first published in the Lexis Nexis Australian Intellectual Property Law Bulletin (newsletter) Volume 26 no 3 September 2013

Key points

  • The Federal Court of Australia recently held that an isolated human gene is patentable, as it is a "method of manufacture".
  • Contrary to the Australian position, the US Supreme Court held that an isolated human gene is not patentable, as it is a "product of nature", which is excluded from patentability under the US Patent Act.
  • The Australian position is unlikely to be affected by the US decision. The Australian government's stance is shifting away from a blanket exclusion and towards implementing safeguards to prevent unconscionable commercial exploitation, such as through research exemptions, compulsory licensing and Crown use, and a ban where commercial exploitation would be wholly offensive.


Angelina Jolie has sparked a renewed public interest in the human gene patents debate with the highly publicised news of her double mastectomy. Since our last article,1 the Australian Federal Court and the US Supreme Court have handed down the latest decisions in the Myriad gene patent cases. Further, major reports from the Productivity Commission and the Centre for International Economics have recently been released, dealing directly with the issues surrounding gene patentability.2

What do these developments mean for the future of gene patenting in Australia?

Are human genes patentable?

Australian position - Cancer Voices Australia v Myriad Genetics Inc

In the landmark decision of Cancer Voices Australia v Myriad Genetics Inc,3 handed down on 15 February 2013, the Federal Court of Australia confirmed the patentability of isolated nucleotide sequences (genes) in Australia.4

The decision relates to the patents held by Myriad Genetics (Myriad) over the BRCA1 and BRCA2 genes, which are used in the diagnosis of breast and ovarian cancer.5 Cancer Voices Australia, a national organisation representing cancer patients, sought revocation of these gene patents.

Under Australian law, the current test for patentability requires an invention to be a "method of manufacture".6 The Federal Court applied the well-established test in the High Court decision of National Research Development Corp v Cmr of Patents7 (NRDC case) to determine whether the isolated DNA was a method of manufacture.

In the NRDC case, the court held that the phrase "method of manufacture" includes a product that consists of "an artificially created state of affairs which has economic significance". The "economic significance" of the claimed invention was not argued by Cancer Voices Australia. Rather, the sole question before the Federal Court was whether the genes isolated by Myriad from its patients constituted "an artificially created state of affairs".

Based on the NRDC case, the Federal Court ruled that the "isolated" nucleic acid that formed the BRCA1 and BRCA2 genes claimed by Myriad existed independently of their originating cells. Accordingly, by definition, the "isolated" nucleic acid did not exist within a cell like "naturally occurring" nucleic acid. The human intervention of isolating the nucleic acid from its "naturally occurring" state constituted "an artificially created state of affairs" and so was a "manner of manufacture" within the meaning of the Patents Act 1990 (Cth).

The Federal Court decision is currently under appeal to the Full Federal Court on the grounds that the court, at first instance, erred in its conclusion that isolating the gene constitutes a manner of manufacture.

US position - Association for Molecular Pathology v Myriad Genetics

Contrary to the Australian position, the Supreme Court of the United States more recently, in Association for Molecular Pathology v Myriad Genetics,8 invalidated Myriad's US patents on the isolated DNA sequences that make up the BRCA1 and BRCA2 genes and their use in Myriad's breast cancer diagnostic tests.9

Under US law as a result of this case, patent claims covering parts of the human genome are "products of nature"10 and therefore not patentable.

The Supreme Court found that it was well established in the scientific community that DNA fragments of the human genome, including the BRCA1 and BRCA2 genes, occur routinely in the human body when cells die and the constituent DNA is broken into fragments. As a result, the Supreme Court held that the genes were products of nature and that mere isolation of the genes did not change the character of the genes as such. Accordingly, the genes were not patentable.

However, the decision does not affect the patentability of gene testing, gene diagnostic methods, and the products of those methods (including cDNA versions of naturally occurring genes).

How will the US decision affect the Australian position?

In our view, the Australian position is unlikely to change in the current appeal to the Full Federal Court, notwithstanding the more recent and contrary US decision. The Full Federal Court is unlikely to take a narrow view of patentable genes in light of the High Court's more liberal approach in the NRDC case, which led to a broadening of Australia's patentability criteria.

Further, the test to determine patentability in Australia is remarkably different from the test that is applied in the United States. In Australia, the court must consider whether the isolated DNA is an "artificially created state of affairs", whereas in the United States the relevant question is whether the isolated DNA is a "product of nature" and therefore not patentable. In light of this differing approach in principle, the Full Federal Court is less likely to attribute significant weight to the contrary US decision when considering the appeal.

Should human genes be patentable?

Underlying this consideration of legal patentability is the normative debate about whether genetic material should or should not be patentable.

No human genes should not be patentable

Advocates for non-patentability of genes argue that genes are natural substances that form part of the human body and ethically should be available to all as part of our common heritage.

Patent expert Luigi Palombi considers that the decision of the Australian Federal Court "ignores human dignity, lacks equity and denies justice to every Australian".11 Palombi argues that the holder of a patent is entitled as a matter of law to an exclusive right to exploitation of the patented subject matter. Therefore, Palombi reasons that granting of a patent over human genes effectively creates a private right to impose a tax on those genes.

Palombi's argument is part of a broader concern that allowing genes to be patented prevents equitable access to medical advice and treatment that relies on the use of gene sequences. Undertaking Myriad's patented test is an expensive endeavour. In the United States, the patented test costs approximately US$3000. In Australia, the test costs A$2000-A$2500 and, for those in families with a history of breast cancer, it costs up to A$1800.

In recent years, the Australian government has undertaken sweeping reforms to patent legislation most notably the enactment of the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth), which raised patent standards and introduced an exemption from patent infringement for research activities.12 IP Australia is currently addressing equitable access concerns, such as those raised by Palombi, in its public consultation of the proposed amendments to the Patents Act.13 In particular, IP Australia is seeking submissions on the government's intention to introduce an exclusion into the legislation that would render inventions unpatentable where commercial exploitation of the invention would be wholly offensive to a reasonable and informed member of the public. Submissions to IP Australia close on 27 September 2013.

Yes human genes should be patentable

The Centre for International Economics (CIE) has recently released its final report investigating the economics of isolated human gene patents in Australia.14 In summary, the report found that patents are generally an important tool for incentivising innovation, recouping costs and offsetting risks associated with commercialisation.

Approximately $795 million was invested in gene technologies related to human health in Australia during 2011-12, with 21% of that coming from private investors.15 Proponents for gene patentability argue that expenditure of this volume would simply not occur without the incentive of market exclusivity provided by the patent system, especially in light of the high risk of failure and the significant costs of capital associated with gene therapy research. Accordingly, on one view, the patent system is conducive to increased social welfare and wellbeing for Australians in that it stimulates the development of new technologies and therapies that would otherwise not have been commercially viable, absent a functioning system of patents.

Further, the CIE's report found that costs often associated with the patenting of human genes, such as the cost of gene diagnostic tests or the inability to improve diagnostic processes, are in fact often caused by factors external to the patent system. These external factors include issues in respect of exclusive licensing, the complexity of the technology, or business relations.

Compulsory licensing and Crown use of human gene patents

In its recent inquiry into the effectiveness of the compulsory licensing provisions in the Patents Act, the Productivity Commission concluded that specifically excluding genes from the patent system is unwarranted. However, the Commission has also recognised that there is a prima facie case for the government to ensure equitable healthcare access.16 Rather than changing the scope of patents, the Commission suggests imposing and strengthening safeguards in the patents system, including safeguards such as compulsory licensing of patents and clarifying the scope of the Crown use of patents.

These two regimes are discussed in more detail below. However, we note that these regimes are rarely used: there have been only three applications for compulsory licences in the last 100 years, none of which have been successful, and two applications for Crown use, both of which have been successful, according to the Productivity Commission Report.

Compulsory licensing

The compulsory licensing provisions in the Patents Act are a key safeguard to ensure that the patent system operates in the interests of the community as a whole. Compulsory licensing operates as an exception to the exclusivity granted by the patent system, providing a mechanism for parties to seek access to patented inventions from a court where certain requirements are met. A compulsory licence may be granted to an applicant where the exercise of the exclusive rights conferred by a patent are not meeting the reasonable requirements of the public or constitute anti-competitive conduct.17

Currently, the Patents Act defines the reasonable requirements of the public by reference to the interests of domestic trade and industries, rather than the broader community. The test of whether a patent is meeting the reasonable requirements of the public turns on whether the interests of domestic trade and industries would be unfairly prejudiced by the patentee's actions.18 Accordingly, the test in its current form could potentially lead to a compulsory licence being issued where the licence would alleviate prejudice to domestic trade or industries but is otherwise not in the interests of the community as a whole. As a result, the Commission has proposed that a public interest test be used instead.

The Commission recommends that the new test should specify that a compulsory licence to exploit the patented invention should only be made available if:

  • Australian demand for a product or service is not being met on reasonable terms, and access to the patented invention is essential for meeting this demand;
  • the applicant has tried for a reasonable period, but without success, to obtain access from the patent owner on reasonable terms and conditions; and
  • there is a substantial public interest in providing access to the applicant, having regard to different factors such as the benefits to the community from meeting the relevant unmet demand and the commercial costs and benefits to the patent holder and licensee from granting access to the patented invention.

The Commission's recommended public interest test provides an access regime for cases where greater use of a patented invention would deliver a substantial net benefit to the community.

Crown use

The Patents Act contains specific provisions for the federal and state governments to use a patented invention without the owner's authorisation (Crown use).19 Governments will generally find Crown use to be a less costly and time-consuming option than compulsory licensing, as there is currently no requirement for the Crown to first attempt to negotiate with the patent owner.

There is some uncertainty as to whether the legislative allowance for Crown use extends to the use of healthcare-related patents. The Productivity Commission identifies some considerations that suggest that Crown use may not cover healthcare-related patents including that, currently, Crown use is specified to allow use "for the services of" a government. Interpreted narrowly, this phrase may exclude healthcare from the ambit of Crown use. Further, Crown use may not cover the provision of healthcare services by non-government organisations.

The Commission proposes that this uncertainty in scope be addressed through a number of means. In particular, the Commission recommends that the Patents Act be amended to make it clear that Crown use can be invoked for the provision of a service that the federal, state and/or territory governments have primary responsibility for providing or funding.

Given that governments are responsible for providing, funding or substantially funding the vast majority of genetic tests, they would be found to have primary responsibility under the amended test. As a result, genetic testing would be eligible for Crown use, including when it is undertaken by private providers for private patients.

Future of human gene patents in Australia

While the cases will ultimately decide the patentability of genetic material, it may have little practical impact on patenting activity in the future. A key finding of the CIE report was that patent activity related to isolated human gene sequence patents has been declining dramatically since the completion of the Human Genome Project in 2003. The CIE report also found that current patent activity is more focused on modified gene sequences or method claims, which are patentable under current laws.20

The issue of the patentability of isolated DNA may also decline in relevance in the next few years as the patents on the BRCA1 and BRCA2 genes are set to expire in August 2015 and December 2015 respectively.21

The government's stance in relation to the patentability of human genes is also shifting away from a blanket exclusion and towards implementing safeguards to prevent unconscionable commercial exploitation, such as through research exemptions, compulsory licensing and Crown use, and a ban where commercial exploitation would be wholly offensive.


1C Logan and W Liu "Patent law update - government signals reforms to address concerns over gene patents" (2012) 25(3) Australian Intellectual Property Law Bulletin 38.

2Productivity Commission Compulsory Licensing of Patents: Productivity Commission Inquiry Report, No 61, 28 March 2013; Centre for International Economics Final Report: Economic Analysis of the Impact of Isolated Human Gene Patents May 2013.

3Cancer Voices Australia v Myriad Genetics Inc (2013) 99 IPR 567; [2013] FCA 65; BC201300552.

4For the procedural history, see L Hartland "Cancer Voices Australia v Myriad Genetics Inc" (2013) 25(9) Australian Intellectual Property Law Bulletin 191.

5BRCA1: Serial nos 686004, 691958; BRCA2: Serial no 773601.

6Patents Act 1990 (Cth), s 18(1)(a).

7National Research Development Corp v Cmr BRCA1: Serial of Patents (NRDC case) (1959) 102 CLR 252; [1960] ALR 114; [1961] RPC 134; BC5900480.

8Association for Molecular Pathology v Myriad Genetics (2013) 569 US 12-398.

9Above, n 1.

10US Patent Act, 35 USC §101.

11L Palombi "Patent law must recognise human genes are no invention" The Drum 20 February 2013, available at

12Specifically, for "experimental purposes": see Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth), s 119C. For a discussion, see P Ng and W Liu "Raising the bar? The new patent law reforms and their impact on patentability of genetic material" (2011) 24(4) Australian Intellectual Property Law Bulletin 87.

13IP Australia Patentable Subject Matter: Consultation on an Objects Clause and an Exclusion from Patentability July 2013, available at

14Above, n 2.

15Above, n 2.

16Above, n 2.

17Patents Act, Ch 12.

18Patents Act, s 135.

19Patents Act, Ch 17 Pt 2.

20Above, n 14.

21Above, n 5.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Catherine Logan
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.